WVENasdaq

Wave Life Sciences Ltd.

Healthcare·Rare Disease·Phase 2·Singapore, Singapore
Rare DiseaseMetabolicGastroenterology

Wave Life Sciences Ltd. (WVE): 5 pipeline candidates · ~28 mo cash runway · 6 clinical trials. Updated within the last hour.

7.4/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway7.7

27.7 months

Financial Health9.4

D/E 0.14 · 4% dilution

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider Signal5.4

4 buys · 8 sells (180d)

A transparent, data-derived signal for Wave Life Sciences Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.1B

Cash

$544.6M

Quarterly Burn

$59.6M

Runway

27.7 mo

Revenue

$38.2M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2028
Today~30 mo out
Catalyst within runway

Pipeline (5 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

233

Total value held

$1.09B

HolderSharesValue
ra capital management, l.p.26,975,505$195.6M
blackrock, inc.14,117,412$102.4M
maverick capital ltd11,317,399$82.1M
driehaus capital management llc5,431,021$39.4M
federated hermes, inc.5,317,457$38.6M
fmr llc5,192,761$37.6M
683 capital management, llc4,900,000$35.5M
primecap management co/ca/4,832,952$35.0M
m28 capital management lp4,588,284$33.3M
state street corp3,674,033$26.6M

Showing top 10 of 233 institutional holders of Wave Life Sciences Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

6 clinical trials·CEO: Dr. Paul B. Bolno M.B.A., M.D.

Frequently asked questions

How many drug candidates are in Wave Life Sciences Ltd.'s pipeline?

Wave Life Sciences Ltd. (WVE) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Wave Life Sciences Ltd.'s lead drug candidate?

Wave Life Sciences Ltd.'s most advanced tracked candidate is WVE-003 (Phase 1/Phase 2) for Huntington's disease (HD).

What is Wave Life Sciences Ltd.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Wave Life Sciences Ltd. has approximately 27.7 months of cash runway.

What is Wave Life Sciences Ltd.'s market capitalization?

Wave Life Sciences Ltd.'s market capitalization is approximately $1.1B.

Who is the CEO of Wave Life Sciences Ltd.?

Dr. Paul B. Bolno M.B.A., M.D. is the chief executive officer of Wave Life Sciences Ltd. (WVE).

Get the full picture on Wave Life Sciences Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.